Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DZ-1-artesunate (DZ-1-ART) is an experimental small molecule drug conjugate consisting of the heptamethine cyanine dye DZ-1 and the antimalarial/anticancer agent artesunate. DZ-1 serves as a tumor-homing and mitochondria-targeting vector, utilizing the high mitochondrial membrane potential of cancer cells to achieve selective intracellular accumulation. Once localized within the mitochondria, the artesunate moiety induces the generation of reactive oxygen species (ROS), which leads to the disruption of mitochondrial membrane potential and the activation of mitochondria-mediated apoptotic pathways. The conjugate also possesses near-infrared (NIR) fluorescence properties, allowing for potential theranostic applications. Research has demonstrated its efficacy in inducing cytotoxicity in patient-derived colorectal cancer tumoroids, suggesting its potential as a precision therapy for malignant neoplasms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DZ-1-artesunate.